Phase II Oncology Trials: Let's Be Positive
Open Access
- 15 August 2005
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 11 (16) , 5661-5662
- https://doi.org/10.1158/1078-0432.ccr-05-1046
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Objective Responses in Patients with Malignant Melanoma or Renal Cell Cancer in Early Clinical Studies Do Not Predict Regulatory ApprovalClinical Cancer Research, 2005
- Final findings from a phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC)Journal of Clinical Oncology, 2005
- Phase II Studies of Modern Drugs Directed Against New Targets: If You Are Fazed, Too, Then Resist RECISTJournal of Clinical Oncology, 2004
- Oncology's trialsNature Reviews Drug Discovery, 2003
- An improved method of evaluating drug effect in a multiple dose clinical trialStatistics in Medicine, 2001
- An introduction to sensitivity, specificity, predictive values and likelihood ratiosEmergency Medicine, 1999
- Learning versus confirming in clinical drug development*Clinical Pharmacology & Therapeutics, 1997
- Statistical and Ethical Issues in the Design and Conduct of Phase I and II Clinical Trials of New Anticancer AgentsJNCI Journal of the National Cancer Institute, 1993